In collaboration with our partner, RG Discovery, we operate an integrated drug discovery platform that leverages our proprietary weak-affinity chromatography (WAC™) fragment screening technology. The advantages of the WAC™ method are outlined on our integrated drug discovery services page. The following steps in the process, including fragment expansion and lead generation, are carried out by experienced medicinal chemists at RG Discovery in close collaboration with our computational chemistry, X-ray crystallography, and protein NMR spectroscopy teams.
